Core Viewpoint - Zhongke Biological (01237) announced the granting of a total of 9.6 million share awards to 11 grantees under the 2025 Share Award Plan, pending acceptance by the grantees [1] Group 1 - The share awards represent the right to receive one share on the vesting date for each awarded share [1]

Core Viewpoint - Zhongke Biological (01237) announced the granting of a total of 9.6 million shares as part of its 2025 share incentive plan, pending acceptance by the grantees [1] Group 1 - The company has awarded shares to 11 grantees under the terms of the share incentive plan [1] - Each share awarded represents the right to receive one share on the vesting date [1]

Core Viewpoint - Zhongke Biological (01237.HK) announced the grant of a total of 9.6 million shares as part of its 2025 share award plan, pending acceptance by the grantees [1] Group 1 - The company will grant shares to 11 grantees under the terms of the 2025 share award plan [1] - Each share awarded represents the right to receive one share on the vesting date [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何 部份內容而產生或因依賴該等內容而引致之任何損失承擔任何責任。 CHINA ENVIRONMENTAL TECHNOLOGY AND BIOENERGY HOLDINGS LIMITED （於開曼群島註冊成立的有限公司） 中科生物控股有限公司 | 授出日期： | 二零二五年十二月五日 | | --- | --- | | 承授人： | 本集團11名經選定僱員 | | 授出的股份獎勵數目： | 合共9,600,000份股份獎勵 | | 所授出股份獎勵的購買價： | 零 | | 股份於授出日期的收市價： | 每股股份0.52港元 | | 歸屬期： | 100% 的股份獎勵將於自授出日期起計第一個週年 | | | 之日歸屬。 | 惟董事會可全權酌情決定該等股份獎勵或其任何 部分應予歸屬。 1 表現目標： 授出的股份獎勵並無附帶表現目標。 薪酬委員會知悉，二零二五年股份獎勵計劃的目的 為就合資格參與者對本集團的貢獻為其提供保留 激勵或獎勵，吸引合適人才以促進本集團發展，並 使承 ...

Core Viewpoint - Ningxia Zhongke Biotechnology Co., Ltd. is currently undergoing a restructuring plan, which may lead to a significant downward adjustment in its stock price due to potential capital reserve increases and other factors [2][3]. Group 1: Stock Price Risks - The company has indicated that its stock price may experience a downward adjustment of approximately 30% following the implementation of the restructuring plan, based on the closing price on December 3, 2025 [2][3]. - The adjustment in stock price will depend on the relationship between the closing price on the capital reserve increase registration date and the average price of the newly issued shares [3]. Group 2: Restructuring Uncertainties - The company has been ruled by the court to terminate the restructuring process and enter the execution phase of the restructuring plan, which carries the risk of being declared bankrupt if the plan is not executed [4]. - If the company is declared bankrupt, it will undergo liquidation, and its stock may face delisting according to the Shanghai Stock Exchange listing rules [4]. Group 3: Additional Risks - There are risks associated with the pre-restructuring investment agreements that have been signed, which may be terminated or become unenforceable [5]. - Other companies under the same group, such as Ningxia Zhongke New Materials Co., Ltd. and Ningxia Xinhai Hengli International Trade Co., Ltd., are also facing similar restructuring challenges and potential bankruptcy risks [6].

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年11月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 中科生物控股有限公司 呈交日期: 2025年12月2日 本月底法定/註冊股本總額： HKD 100,000,000 FF301 第 1 頁 共 10 頁 v 1.1.1 FF301 II. 已發行股份及/或庫存股份變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01237 | 說明 | | | | | | | | | 已發行股份（不包括庫存股份）數目 | | 庫存股份數目 | | 已發行股份總數 | | | 上月底結存 | | | 96,037,051 | | 0 | | 96,037,051 | | 增加 / 減少 (-) | | | | | | | | | 本月底結存 | | | 96,037,051 | | 0 | | 96,037,05 ...

Core Viewpoint - The announcement indicates a significant change in the ownership structure of Ningxia Zhongke Biological Technology Co., Ltd. due to the execution of its restructuring plan, resulting in Hunan Xinhong Pharmaceutical Co., Ltd. becoming the controlling shareholder and Liu Xirong as the actual controller [1][3][5]. Group 1: Basic Situation of the Equity Change - The court has approved the restructuring plan for the company, leading to the termination of its restructuring process [2][3]. - The total share capital of the company will increase from 684,883,775 shares to 1,615,883,775 shares after a capital reserve conversion, with 931,000,000 shares being issued [3][51]. - Hunan Xinhong will hold 357,142,857 shares, representing 22.10% of the total share capital post-conversion, thus becoming the controlling shareholder [1][5]. Group 2: Changes in Shareholding Structure - Before the equity change, Shanghai Zhongneng held 200,000,000 shares (29.20% of total shares), which will decrease to 12.38% after the change [5][17]. - The actual controller will shift from Yu Jianming to Liu Xirong following the equity change [5][49]. Group 3: Subsequent Matters - Hunan Xinhong and Shanghai Zhongneng are required to prepare equity change reports as per regulations [5][6]. - The restructuring investment involves a cash payment of 400 million yuan for the shares acquired by Hunan Xinhong, with a lock-up period of 36 months [51][60].

Core Viewpoint - The announcement details the progress of the second judicial auction of shares held by the controlling shareholder of Ningxia Zhongke Biotechnology Co., Ltd., indicating that the shares have been auctioned and the outcome is pending further legal procedures [2][4]. Group 1: Shareholding and Auction Details - Shanghai Zhongneng Enterprise Development (Group) Co., Ltd. holds 200,000,000 shares of Ningxia Zhongke, accounting for 29.20% of the total share capital, with all shares pledged and frozen [2][3]. - The second judicial auction for the 200,000,000 shares took place from November 17 to November 18, 2025, on the JD Network Judicial Auction platform [4][5]. - The auction results indicate that the shares were successfully bid on, with the final transaction subject to the court's auction ruling [5][6]. Group 2: Future Steps and Uncertainties - Following the auction, there are still steps involving the payment of auction proceeds, legal execution procedures, and the transfer of share ownership, which introduces uncertainty regarding the final outcome [2][6]. - If the shares are fully transferred, Shanghai Zhongneng will no longer hold any shares in the company [2][6]. - The company will closely monitor the situation and fulfill its information disclosure obligations as required by relevant laws and regulations [2][6].

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 中科生物控股有限公司 呈交日期: 2025年11月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01237 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 200,000,000 | HKD | | 0.5 | HKD | | 100,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 200,000,000 | HKD | | 0.5 | HKD | | 100,000,000 | 本月底法定/註冊股本總額 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈之內容概不負責 ，對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公佈全部或任 何部份內容而產生或因依賴該等內容而引致之任何損失承擔任何責任。 | | 普通決議案 | 票數（概約%） | | | --- | --- | --- | --- | | | | 贊成 | 反對 | | 1. | 批准二零二五年股份獎勵計劃 | 26,052,697 | 20,000 | | | | (99.92%) | (0.08%) | | 2. | 批准服務提供商分項限額 | 26,052,697 | 20,000 | | | | (99.92%) | (0.08%) | CHINA ENVIRONMENTAL TECHNOLOGY AND BIOENERGY HOLDINGS LIMITED 中科生物控股有限公司 （於開曼群島註冊成立之有限公司） （股份代號：1237） 股東特別大會投票表決結果 茲提述中科生物控股有限公司（「本公司」）日期為二零二五年九月二十二日的 通函（「通函」）。本公告所用詞彙與通函所界定者具有相同涵義。 董事會欣然宣佈，股東特別大會通告所載 ...